MX2022012844A - Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. - Google Patents
Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.Info
- Publication number
- MX2022012844A MX2022012844A MX2022012844A MX2022012844A MX2022012844A MX 2022012844 A MX2022012844 A MX 2022012844A MX 2022012844 A MX2022012844 A MX 2022012844A MX 2022012844 A MX2022012844 A MX 2022012844A MX 2022012844 A MX2022012844 A MX 2022012844A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- same
- histone deacetylase
- inhibitor
- hdac6
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 1,3,4-oxadiazole derivative compounds Chemical class 0.000 title 1
- 229940122617 Histone deacetylase 6 inhibitor Drugs 0.000 title 1
- 102000011427 Histone Deacetylase 6 Human genes 0.000 abstract 4
- 108010023925 Histone Deacetylase 6 Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000003287 optical effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un nuevo compuesto que tiene una actividad inhibidora de histona desacetilasa 6 (HDAC6), un isómero óptico del mismo o una sal farmacéuticamente aceptable del mismo, al uso del mismo para preparar un medicamento terapéutico, una composición farmacéutica que contiene la misma, y un método de tratamiento que usa la composición y un método de preparación de la misma. El nuevo compuesto, el isómero óptico del mismo o la sal farmacéuticamente aceptable del mismo, de acuerdo con la presente invención, tiene la actividad inhibidora de HDAC6, que es eficaz en la prevención o el tratamiento de enfermedades mediadas por HDAC6, incluyendo cáncer, enfermedades inflamatorias, enfermedades autoinmunitarias, enfermedades neurológicas o neurodegenerativas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200044730A KR102576148B1 (ko) | 2020-04-13 | 2020-04-13 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| PCT/KR2021/004544 WO2021210857A1 (en) | 2020-04-13 | 2021-04-12 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012844A true MX2022012844A (es) | 2022-11-07 |
Family
ID=78084333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012844A MX2022012844A (es) | 2020-04-13 | 2021-04-12 | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230278995A1 (es) |
| EP (1) | EP4136085A4 (es) |
| JP (1) | JP7492033B2 (es) |
| KR (1) | KR102576148B1 (es) |
| CN (1) | CN115427406A (es) |
| AU (1) | AU2021255176B2 (es) |
| BR (1) | BR112022020731A2 (es) |
| CA (1) | CA3174319A1 (es) |
| MX (1) | MX2022012844A (es) |
| TW (1) | TWI807300B (es) |
| WO (1) | WO2021210857A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI600638B (zh) * | 2010-01-22 | 2017-10-01 | 艾斯特隆製藥公司 | 作爲蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法 |
| EP2563787B1 (en) * | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
| US9278910B2 (en) * | 2011-05-31 | 2016-03-08 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
| WO2013134467A1 (en) | 2012-03-07 | 2013-09-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
| RU2697665C1 (ru) * | 2015-07-27 | 2019-08-16 | Чонг Кун Данг Фармасьютикал Корп. | Производные 1,3,4-оксадиазолсульфонамида в качестве ингибиторов деацетилазы гистонов 6 и фармацевтическая композиция, содержащая их |
| NZ739211A (en) * | 2015-07-27 | 2019-05-31 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
| CA2994688C (en) * | 2015-08-04 | 2020-11-03 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| EP3475275B1 (en) * | 2016-06-23 | 2024-04-10 | Merck Sharp & Dohme LLC | 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| AU2018379321B2 (en) * | 2017-12-05 | 2024-05-16 | Oryzon Genomics, S.A. | 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors |
-
2020
- 2020-04-13 KR KR1020200044730A patent/KR102576148B1/ko active IP Right Grant
-
2021
- 2021-04-12 WO PCT/KR2021/004544 patent/WO2021210857A1/en active Application Filing
- 2021-04-12 CN CN202180027885.2A patent/CN115427406A/zh active Pending
- 2021-04-12 JP JP2022562330A patent/JP7492033B2/ja active Active
- 2021-04-12 MX MX2022012844A patent/MX2022012844A/es unknown
- 2021-04-12 CA CA3174319A patent/CA3174319A1/en active Pending
- 2021-04-12 BR BR112022020731A patent/BR112022020731A2/pt unknown
- 2021-04-12 EP EP21789004.5A patent/EP4136085A4/en active Pending
- 2021-04-12 US US17/995,947 patent/US20230278995A1/en active Pending
- 2021-04-12 TW TW110113120A patent/TWI807300B/zh active
- 2021-04-12 AU AU2021255176A patent/AU2021255176B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202200568A (zh) | 2022-01-01 |
| AU2021255176A1 (en) | 2022-10-13 |
| KR20210126970A (ko) | 2021-10-21 |
| US20230278995A1 (en) | 2023-09-07 |
| JP7492033B2 (ja) | 2024-05-28 |
| BR112022020731A2 (pt) | 2022-11-29 |
| JP2023521836A (ja) | 2023-05-25 |
| KR102576148B1 (ko) | 2023-09-07 |
| EP4136085A1 (en) | 2023-02-22 |
| WO2021210857A1 (en) | 2021-10-21 |
| TWI807300B (zh) | 2023-07-01 |
| CA3174319A1 (en) | 2021-10-21 |
| AU2021255176B2 (en) | 2024-01-18 |
| CN115427406A (zh) | 2022-12-02 |
| EP4136085A4 (en) | 2024-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| NZ739211A (en) | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same | |
| PH12016501735A1 (en) | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
| NZ740429A (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| PH12017501939B1 (en) | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| MX2018004447A (es) | Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. | |
| MX2022010394A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. | |
| MX2022010402A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. | |
| MX2023000625A (es) | Nuevos compuestos como inhibidor de histona desacetilasa 6, y composicion farmaceutica que los comprende. | |
| MX2021014372A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. | |
| PH12021550039A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | |
| MX2022010748A (es) | Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1). | |
| MX2023002547A (es) | Compuestos novedosos como inhibidor de histona desacetilasa 6 y composicion farmaceutica que comprende los mismos. | |
| MX2017014953A (es) | Compuestos derivados de alquilos heterociclicos como inhibidores de histona desacetilasa selectivos y composiciones farmaceuticas que los comprenden. | |
| MX2022012844A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. | |
| MX2022013273A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso. | |
| MX2021014315A (es) | Compuestos derivados de 1,3,4-oxadiazol homoftalimida como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. | |
| MX2023006193A (es) | Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina. | |
| WO2020145831A8 (en) | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases | |
| MX2021002742A (es) | Terapia combinada con un inhibidor de la fosfoinositida 3-quinasa con un resto de unión a zinc. | |
| TW202421119A (zh) | 作為組蛋白去乙醯酶６抑制劑之１，３，４－㗁二唑衍生化合物及其用途 | |
| WO2023039226A3 (en) | Treatments and methods for treating alzheimer's disease | |
| WO2022048618A8 (en) | Methods to treat inflammatory bowel disease | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| TW202421103A (zh) | 苯烷胺及其製造與使用方法 |